CN1914201A - 烟碱乙酰胆碱受体配体 - Google Patents

烟碱乙酰胆碱受体配体 Download PDF

Info

Publication number
CN1914201A
CN1914201A CNA2004800412932A CN200480041293A CN1914201A CN 1914201 A CN1914201 A CN 1914201A CN A2004800412932 A CNA2004800412932 A CN A2004800412932A CN 200480041293 A CN200480041293 A CN 200480041293A CN 1914201 A CN1914201 A CN 1914201A
Authority
CN
China
Prior art keywords
disease
atoms
oxygen
sulfur
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800412932A
Other languages
English (en)
Chinese (zh)
Inventor
格伦·欧内斯特
罗伯特·雅各布斯
艾菲奥恩·菲利普斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CN1914201A publication Critical patent/CN1914201A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CNA2004800412932A 2003-12-22 2004-12-20 烟碱乙酰胆碱受体配体 Pending CN1914201A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53171203P 2003-12-22 2003-12-22
US60/531,712 2003-12-22

Publications (1)

Publication Number Publication Date
CN1914201A true CN1914201A (zh) 2007-02-14

Family

ID=34710246

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2004800412932A Pending CN1914201A (zh) 2003-12-22 2004-12-20 烟碱乙酰胆碱受体配体

Country Status (14)

Country Link
US (1) US20070270458A1 (https=)
EP (1) EP1699786A1 (https=)
JP (1) JP2007515478A (https=)
KR (1) KR20060125812A (https=)
CN (1) CN1914201A (https=)
AU (1) AU2004303737A1 (https=)
BR (1) BRPI0417927A (https=)
CA (1) CA2550844A1 (https=)
IL (1) IL176071A0 (https=)
MX (1) MXPA06007026A (https=)
NO (1) NO20063356L (https=)
SG (1) SG149052A1 (https=)
WO (1) WO2005061494A1 (https=)
ZA (1) ZA200605074B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102918021A (zh) * 2010-05-27 2013-02-06 塔加西普特公司 烟碱受体非竞争性拮抗剂

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012007500A2 (de) 2010-07-15 2012-01-19 Bayer Cropscience Ag Neue heterocyclische verbindungen als schädlingsbekämpfungsmittel
WO2021174174A1 (en) * 2020-02-28 2021-09-02 Remix Therapeutics Inc. Thiophenyl derivatives useful for modulating nucleic acid splicing

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2529548A1 (fr) * 1982-07-02 1984-01-06 Delalande Sa Nouveaux derives de l'amino-3 quinuclidine, leur procede et leur application en therapeutique
DE3852145T2 (de) * 1987-02-18 1995-04-06 Beecham Group Plc Indolderivate, Verfahren zu deren Herstellung und pharmazeutische Präparate, die diese enthalten.
SE0000540D0 (sv) * 2000-02-18 2000-02-18 Astrazeneca Ab New compounds
WO2002017358A2 (en) * 2000-08-21 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists)
US6599916B2 (en) * 2000-08-21 2003-07-29 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
EP1311505A2 (en) * 2000-08-21 2003-05-21 PHARMACIA & UPJOHN COMPANY Quinuclidine-substituted heteroaryl moieties for treatment of disease ( nicotinic acetylcholine receptor ligands )
DE10156719A1 (de) * 2001-11-19 2003-05-28 Bayer Ag Heteroarylcarbonsäureamide

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102918021A (zh) * 2010-05-27 2013-02-06 塔加西普特公司 烟碱受体非竞争性拮抗剂
CN102918021B (zh) * 2010-05-27 2015-02-11 塔加西普特公司 烟碱受体非竞争性拮抗剂

Also Published As

Publication number Publication date
AU2004303737A1 (en) 2005-07-07
CA2550844A1 (en) 2005-07-07
KR20060125812A (ko) 2006-12-06
BRPI0417927A (pt) 2007-04-17
SG149052A1 (en) 2009-01-29
WO2005061494A1 (en) 2005-07-07
ZA200605074B (en) 2007-05-30
US20070270458A1 (en) 2007-11-22
IL176071A0 (en) 2006-10-05
JP2007515478A (ja) 2007-06-14
MXPA06007026A (es) 2006-08-31
EP1699786A1 (en) 2006-09-13
NO20063356L (no) 2006-09-21

Similar Documents

Publication Publication Date Title
CN1205210C (zh) 作为尼古丁ACh受体上胆碱能配体的9－氮杂双环(3.3.1)壬－2－烯衍生物
JP5121716B2 (ja) ピリジン誘導体および精神異常の処置におけるそれらの使用
CN1423651A (zh) 新的用途和新的n－氮杂双环－酰胺衍生物
CN1662542A (zh) 杂环化合物
CN1675215A (zh) 作为烟碱性乙酰胆碱拮抗剂的芳基取代的二氮杂双环烷烃
CN1662541A (zh) 呋喃基化合物
JP2004526788A (ja) 疾患治療用の置換型アザ二環式基（ニコチン性アセチルコリン受容体アンタゴニスト）
WO2002016358A2 (en) Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands)
WO2002016357A2 (en) Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands)
JP2009507801A5 (https=)
CN1659170A (zh) 噻吩基化合物
US7566727B2 (en) 2-(1-aza-bicyclo[2.2.2]oct-3-yl)-2,3-dihydro-isoindole-1-one/5,6-dihydro-furo[2,3-c] pyrrol-4-one derivative ligands for alpha 7 nicotinic acetylcholine receptor
WO2002016356A2 (en) Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands)
US20030130305A1 (en) Azabicyclic-phenyl-fused-heterocyclic compounds for treatment of disease
EP1438308A1 (en) N-azabicyclo-substituted hetero-bicyclic carboxamides as nachr agonists
EP3174882A1 (en) 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5h)-one compounds and their use as negative allosteric modulators of mglur2 receptors
JP5084731B2 (ja) ドーパミンｄ３受容体の調節因子としてのアザビシクロ［３．１．０］ヘキシルフェニル誘導体
CA2954218A1 (en) 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5h)-one compounds and their use as negative allosteric modulators of mglur2 receptors
CN1278258A (zh) 氮杂环醚衍生物及其作为烟碱乙酰胆碱受体调节剂的应用
CN1918166A (zh) 烟碱乙酰胆碱受体配体
CN1914201A (zh) 烟碱乙酰胆碱受体配体
CN1910190A (zh) 环氨基取代的噻吩并嘧啶和噻吩并吡啶衍生物
CN1257485A (zh) 氮杂环辛烷和庚烷衍生物、其制备方法和治疗用途
CN1914200A (zh) 烟碱性乙酰胆碱受体配件
CN1882584A (zh) 4－取代的咪唑

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication